Despite the large number of new medicines entering the market every year, the vast majority offer few clinical advantages for patients over existing alternatives. Governments and pharmaceutical companies share the responsibility for this innovation deficit in the sector
There is an increasingly urgent need for new antibiotics, yet there is a significant and persistent ...
In spite of a growing literature on pharmaceuticalization, little is known about the pharmaceutical ...
Modern medicine faces many significant problems. This Article is about two of them. The first is tha...
Despite the large number of new medicines entering the market every year, the vast majority offer fe...
A host of challenges confront healthcare authorities worldwide. Topping the list is the demand for i...
The rate of new drug approvals in the US has remained essentially constant since 1950, while the cos...
This article contends that poor economic incentives are an important reason for the lack of new drug...
The manufacture of pharmaceuticals is big business. From 1995 to 1999, for example, the value of med...
By 2014, the worldwide annual spend on medicines is expected to exceed one trillion dollars, represe...
Despite methodological concerns, comparative efficacy evidence should be required at the time of dru...
The article aimed to give a personal perspective on drug discovery and development. The author has w...
The process for approving new drugs for type 2 diabetes illustrates the significant shortcomings of ...
There is an increasingly urgent need for new antibiotics, yet there is a significant and persistent ...
What is your opinion on the current state of the pharmaceutical industry? The pharmaceutical industr...
There is an increasingly urgent need for new antibiotics, yet there is a significant and persistent ...
There is an increasingly urgent need for new antibiotics, yet there is a significant and persistent ...
In spite of a growing literature on pharmaceuticalization, little is known about the pharmaceutical ...
Modern medicine faces many significant problems. This Article is about two of them. The first is tha...
Despite the large number of new medicines entering the market every year, the vast majority offer fe...
A host of challenges confront healthcare authorities worldwide. Topping the list is the demand for i...
The rate of new drug approvals in the US has remained essentially constant since 1950, while the cos...
This article contends that poor economic incentives are an important reason for the lack of new drug...
The manufacture of pharmaceuticals is big business. From 1995 to 1999, for example, the value of med...
By 2014, the worldwide annual spend on medicines is expected to exceed one trillion dollars, represe...
Despite methodological concerns, comparative efficacy evidence should be required at the time of dru...
The article aimed to give a personal perspective on drug discovery and development. The author has w...
The process for approving new drugs for type 2 diabetes illustrates the significant shortcomings of ...
There is an increasingly urgent need for new antibiotics, yet there is a significant and persistent ...
What is your opinion on the current state of the pharmaceutical industry? The pharmaceutical industr...
There is an increasingly urgent need for new antibiotics, yet there is a significant and persistent ...
There is an increasingly urgent need for new antibiotics, yet there is a significant and persistent ...
In spite of a growing literature on pharmaceuticalization, little is known about the pharmaceutical ...
Modern medicine faces many significant problems. This Article is about two of them. The first is tha...
DOI
Add to ORKG